Sumitomo Mitsui DS Asset Management Company Ltd Buys 133 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 5,951 shares of the medical research company’s stock after acquiring an additional 133 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Charles River Laboratories International were worth $1,099,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Empirical Finance LLC increased its holdings in Charles River Laboratories International by 4.2% during the 3rd quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock worth $258,000 after purchasing an additional 53 shares during the period. OLD National Bancorp IN grew its position in shares of Charles River Laboratories International by 3.1% during the 3rd quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company’s stock worth $392,000 after buying an additional 59 shares in the last quarter. Fiduciary Financial Group LLC increased its stake in shares of Charles River Laboratories International by 3.9% during the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock valued at $310,000 after buying an additional 63 shares during the period. Pinnacle Bancorp Inc. raised its holdings in shares of Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 65 shares in the last quarter. Finally, M&T Bank Corp lifted its stake in Charles River Laboratories International by 3.4% in the third quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock worth $394,000 after acquiring an additional 66 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on CRL. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. UBS Group restated a “neutral” rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. CLSA downgraded Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a report on Monday, November 18th. The Goldman Sachs Group decreased their price objective on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. Finally, Bank of America cut their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Three analysts have rated the stock with a sell rating, fourteen have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat, Charles River Laboratories International has a consensus rating of “Hold” and a consensus target price of $200.79.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $154.93 on Wednesday. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a twelve month low of $154.01 and a twelve month high of $275.00. The company’s 50 day moving average is $178.90 and its 200 day moving average is $192.24. The company has a market cap of $7.92 billion, a PE ratio of 19.39, a price-to-earnings-growth ratio of 6.47 and a beta of 1.37.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).